Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTA-HYNIC-panPSMA
- Development stage
- Unknown
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
177Lu-DOTA-HYNIC-panPSMA (also known as TLX597-Tx or TLX597) is an investigational, next-generation small-molecule radioligand therapy (RLT) being developed by Telix Pharmaceuticals. The drug consists of the beta-emitting radionuclide lutetium-177 (177Lu) chelated by DOTA and conjugated to a HYNIC-linked panPSMA ligand. It is designed to target prostate-specific membrane antigen (PSMA), which is highly overexpressed on prostate cancer cells. Upon binding, the radiopharmaceutical is internalized, delivering targeted ionizing radiation that induces DNA damage and cell death. Due to its optimized design, 177Lu-DOTA-HYNIC-panPSMA exhibits a highly favorable dosimetry profile with significantly reduced uptake in healthy organs, such as the salivary glands and kidneys, potentially minimizing off-target toxicities like xerostomia and renal impairment. It is currently being evaluated in Phase 2 clinical trials, including the OPTIMAL-PSMA study for metastatic castration-resistant prostate cancer (mCRPC) and the OPTIMAL-e study for metastatic hormone-sensitive prostate cancer (mHSPC).
- Other names
- 177Lu-DOTA-HYNIC-panPSMA177Lu-PSMA-597PSMA-597PSMA597PSMA 597lutetium-177 DOTA-HYNIC-panPSMAlutetium177 DOTA-HYNIC-panPSMAlutetium 177 DOTA-HYNIC-panPSMA
02
Targets
DNAPSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-DOTA-HYNIC-panPSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTA-HYNIC-panPSMA.